Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Matrixyl cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Matrixyl cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Matrixyl combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Matrixyl cycle length?
No. We found no human studies that report a treatment duration for Matrixyl.
What is the longest human study of Matrixyl?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Matrixyl dosing reference Full research page

References

  1. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin Int J Cosmet Sci. 2005
  2. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts Mol Pharm. 2013
  3. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet J Clin Aesthet Dermatol. 2023
  4. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS) Biomol Ther (Seoul). 2014
  5. Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing ACS Omega. 2022
  6. Microneedle enhanced delivery of cosmeceutically relevant peptides in human skin PLoS One. 2014
  7. Palmitoyl Pentapeptide-4 (CID 9897237) PubChem. 2026
  8. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and alpha-Smooth Muscle Actin Expression Tissue Eng Regen Med. 2017
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); no entry for palmitoyl pentapeptide or matrixyl in any of the three categories FDA. 2026
  10. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  11. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization Pharmaceutics. 2024